Literature DB >> 11150029

Bone marrow-disseminated tumor cells in patients with carcinoma of the esophagus or cardia.

L Bonavina1, D Soligo, N Quirici, P Bossolasco, B Cesana, G Lembertenghi Deliliers, A Peracchia.   

Abstract

BACKGROUND: The long-term prognosis after surgical therapy for esophageal carcinoma depends on tumor stage and completeness of resection. Similarly to other epithelial tumors, the presence of micro deposits of neoplastic cells in the bone marrow may indicate residual disease and the potential for recurrence. This study assesses the prevalence of bone marrow-disseminated tumor cells in patients undergoing surgical resection for esophageal carcinoma. In addition, we investigated the agreement between immunohistochemical and molecular techniques for the detection of micrometastases in a subgroup of patients.
METHODS: Between January 1998 and November 1999, forty-eight patients with adenocarcinoma of the esophagogastric junction (n = 29) or squamous cell carcinoma of the thoracic esophagus (n = 19) and no evidence of overt metastatic disease entered the study. An immunohistochemical assay (capable of detecting 1 carcinoma cell in 7 x 10(5) bone marrow cells) was used to test bone marrow obtained by flushing a resected rib or by needle aspiration either of the iliac crest or of a rib. A polymerase chain reaction (PCR) molecular technique was also used to identify bone marrow and peripheral blood epithelial cells.
RESULTS: Cytokeratin-positive cells were found in 79.1% of the bone marrow samples obtained from the rib, and in only 8% of the needle aspirates either from the iliac crest or from a contiguous rib: This difference is probably explained by the improved removal of metastatic cells with the flushing of the rib. Comparable results were obtained at a qualitative level by the PCR technique on bone marrow. In addition, PCR-positive results were found in 3 of 18 peripheral blood samples. There was no association with tumor type, neoadjuvant therapy, or lymph node status. Patients with a pT3 or pT4 tumor showed, at a borderline statistical level, a higher proportion of cytokeratin-positive cells in the flushed rib.
CONCLUSIONS: Bone marrow-disseminated tumor cells are present in the resected rib of a high proportion of patients undergoing esophagectomy for carcinoma, and immunohistochemistry seems to be the method of choice for their quantitative assessment. However, the prognostic and therapeutic implications of this finding need further investigation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11150029     DOI: 10.1067/msy.2001.109503

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  14 in total

1.  Lymph node, peritoneal and bone marrow micrometastases in gastric cancer: Their clinical significance.

Authors:  John Griniatsos; Othon Michail; Nikoletta Dimitriou; Ioannis Karavokyros
Journal:  World J Gastrointest Oncol       Date:  2012-02-15

Review 2.  [Minimal residual tumor in gastrointestinal carcinoma. Relevance to prognosis and oncologic surgical consequences].

Authors:  S Gretschel; A Bembenek; T Schulze; W Kemmner; P M Schlag
Journal:  Chirurg       Date:  2006-12       Impact factor: 0.955

3.  Detection of lymph node involvement by cytokeratin immunohistochemistry is an independent prognostic factor after curative resection of esophageal cancer.

Authors:  Goran Marjanovic; Markus Schricker; Axel Walch; Axel zur Hausen; Ulrich T Hopt; Andreas Imdahl; Frank Makowiec
Journal:  J Gastrointest Surg       Date:  2010-10-26       Impact factor: 3.452

4.  Lymph node micrometastases detected by carcinoembryonic antigen mRNA affect long-term survival and disease-free interval in early-stage lung cancer patients.

Authors:  Mario Nosotti; Alessandro Palleschi; Lorenzo Rosso; Davide Tosi; Luigi Santambrogio; Paolo Mendogni; Antonella Marzorati; Ilaria Righi; Silvano Bosari
Journal:  Oncol Lett       Date:  2012-08-24       Impact factor: 2.967

Review 5.  Western strategy for EGJ carcinoma.

Authors:  Simone Giacopuzzi; Maria Bencivenga; Jacopo Weindelmayer; Giuseppe Verlato; Giovanni de Manzoni
Journal:  Gastric Cancer       Date:  2016-12-30       Impact factor: 7.370

6.  Results of surgical therapy in patients with Barrett's adenocarcinoma.

Authors:  Luigi Bonavina; Albert Via; Raffaello Incarbone; Greta Saino; Alberto Peracchia
Journal:  World J Surg       Date:  2003-08-18       Impact factor: 3.352

7.  The presence of bone marrow cytokeratin-immunoreactive cells does not predict outcome in gastric cancer patients.

Authors:  G de Manzoni; G Pelosi; F Pavanel; A Di Leo; C Pedrazzani; E Durante; C Cordiano; F Pasini
Journal:  Br J Cancer       Date:  2002-04-08       Impact factor: 7.640

Review 8.  Preoperative therapy in locally advanced esophageal cancer.

Authors:  Pankaj Kumar Garg; Jyoti Sharma; Ashish Jakhetiya; Aakanksha Goel; Manish Kumar Gaur
Journal:  World J Gastroenterol       Date:  2016-10-21       Impact factor: 5.742

9.  The effects of preoperative chemotherapy on isolated tumour cells in the blood and bone marrow of gastric cancer patients.

Authors:  P Kolodziejczyk; A Pituch-Noworolska; G Drabik; J Kulig; A Szczepanik; M Sierzega; A Gurda; T Popiela; M Zembala
Journal:  Br J Cancer       Date:  2007-08-14       Impact factor: 7.640

10.  Prognostic significance of prospectively detected bone marrow micrometastases in esophagogastric cancer: 10-year follow-up confirms prognostic significance.

Authors:  Paul Ryan; Heidi Furlong; Conleth G Murphy; Finbarr O'Sullivan; Thomas N Walsh; Fergus Shanahan; Gerald C O'Sullivan
Journal:  Cancer Med       Date:  2015-04-27       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.